DGX — Quest Diagnostics Incorporated stock price and chart

DGX

Quest Diagnostics IncorporatedStock · HealthcareS&P 500 Equal Weight 0.2% · S&P 500 0.04% · Russell 1000 0.03% · US Stock Market 0.03% · Russell 3000 0.03% · MSCI World 0.02% · MSCI ACWI 0.02%

$235.02+1.68%

as of market close, Sep 11, 2026

☾ AH — —

PeersMRNALLYUNHJNJMRKABBV

Technical analysis2

Overlay lines0

Addendum charts0

VolumeDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD

20162019202120242026

80.0100.0120.0140.0160.0180.0200.0220.0240.0010.0M$235.02

2026-09-11

Price$235.02

MA20$210.81

MA50$194.73

Vol5.4M

What would $1,000 invested in DGX be worth today? →

DGX returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $235.02
Change YTD: +37.20%
Next earnings: Oct 20, 2026
Market cap: 25.9B2016-09 11.7B2026-09 25.9B+121.1% over the window
Enterprise value: 32B
Shares outstanding: 110.4M2016-06 139M2026-06 110.4M-20.6% over the window
52W low: $171.18
52W high: $247.19
From 52W high: -4.92%
From 52W low: +37.29%
52W range: 84%
Beta: 0.55

Volume

Rel volume: 1.19×
30D volume: 840.8K
30D $ vol: 200.4M

Fundamentals

Sales (ttm): 11.6B2016-06 7.5B2026-06 11.6B+54.2% over the window
Sales/share: $104.742016-06 $53.942026-06 $104.74+94.2% over the window
EPS (ttm): $9.442016-06 $5.722026-06 $9.44+65.0% over the window
FCF (ttm): 1.3B2016-06 698M2026-06 1.3B+93.3% over the window
FCF/share: $12.222016-06 $5.022026-06 $12.22+143.4% over the window
Book value/share: $68.102016-06 $32.642026-06 $68.10+108.7% over the window
Net margin: 9.19%2016-06 11.0%2026-06 9.2%-16.8% over the window
ROE: 14.13%2016-06 18.2%2026-06 14.1%-22.6% over the window
ROA: 6.27%2016-06 8.2%2026-06 6.3%-23.5% over the window
Debt / equity: 0.75×2016-06 0.852026-06 0.75-11.3% over the window
Current ratio: 1.592016-06 1.362026-06 1.59+17.0% over the window

Growth (CAGR, ttm) · 10Y

Sales: +9.87%2025-06-30 → 2026-06-3010.5B → 11.6B (+9.9% total)+6.80%2023-06-30 → 2026-06-309.5B → 11.6B (+21.8% total)+0.89%2021-06-30 → 2026-06-3011.1B → 11.6B (+4.5% total)+4.42%2016-06-30 → 2026-06-307.5B → 11.6B (+54.2% total)
Net income: +11.80%2025-06-30 → 2026-06-30950M → 1.1B (+11.8% total)+10.18%2023-06-30 → 2026-06-30794M → 1.1B (+33.8% total)-13.92%2021-06-30 → 2026-06-302.2B → 1.1B (-52.7% total)+2.52%2016-06-30 → 2026-06-30828M → 1.1B (+28.3% total)
FCF: +10.22%2025-06-30 → 2026-06-301.2B → 1.3B (+10.2% total)+15.39%2023-06-30 → 2026-06-30878M → 1.3B (+53.6% total)-9.08%2021-06-30 → 2026-06-302.2B → 1.3B (-37.9% total)+6.81%2016-06-30 → 2026-06-30698M → 1.3B (+93.3% total)
Shares: -1.30%2025-06-30 → 2026-06-30111.8M → 110.4M (-1.3% total)-0.56%2023-06-30 → 2026-06-30112.2M → 110.4M (-1.7% total)-2.01%2021-06-30 → 2026-06-30122.2M → 110.4M (-9.7% total)-2.28%2016-06-30 → 2026-06-30139M → 110.4M (-20.6% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +13.04%2025-06-30 → 2026-06-30$8.35 → $9.44 (+13.0% total)+10.99%2023-06-30 → 2026-06-30$6.90 → $9.44 (+36.7% total)-10.86%2021-06-30 → 2026-06-30$16.77 → $9.44 (-43.7% total)+5.14%2016-06-30 → 2026-06-30$5.72 → $9.44 (+65.0% total)
Sales/share: +11.32%2025-06-30 → 2026-06-30$94.09 → $104.74 (+11.3% total)+7.40%2023-06-30 → 2026-06-30$84.54 → $104.74 (+23.9% total)+2.96%2021-06-30 → 2026-06-30$90.51 → $104.74 (+15.7% total)+6.86%2016-06-30 → 2026-06-30$53.94 → $104.74 (+94.2% total)
FCF/share: +11.67%2025-06-30 → 2026-06-30$10.95 → $12.22 (+11.7% total)+16.03%2023-06-30 → 2026-06-30$7.82 → $12.22 (+56.2% total)-7.21%2021-06-30 → 2026-06-30$17.77 → $12.22 (-31.2% total)+9.31%2016-06-30 → 2026-06-30$5.02 → $12.22 (+143.4% total)
Book value/share: +5.35%2025-06-30 → 2026-06-30$64.64 → $68.10 (+5.4% total)+6.94%2023-06-30 → 2026-06-30$55.68 → $68.10 (+22.3% total)+7.12%2021-06-30 → 2026-06-30$48.28 → $68.10 (+41.0% total)+7.63%2016-06-30 → 2026-06-30$32.64 → $68.10 (+108.7% total)
Dividend/share: +7.10%2025-06-30 → 2026-06-30$3.10 → $3.32 (+7.1% total)+6.61%2023-06-30 → 2026-06-30$2.74 → $3.32 (+21.2% total)+7.07%2021-06-30 → 2026-06-30$2.36 → $3.32 (+40.7% total)+7.85%2016-06-30 → 2026-06-30$1.56 → $3.32 (+112.8% total)
Price: +28.13%2025-09-11 → 2026-09-11$183.46 → $235.02 (+28.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+22.86%2023-09-11 → 2026-09-11$126.71 → $235.02 (+85.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+8.69%2021-09-10 → 2026-09-11$154.94 → $235.02 (+51.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+11.25%2016-09-09 → 2026-09-11$80.92 → $235.02 (+190.4% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +30.38%2025-09-11 → 2026-09-11$180.30 → $235.02 (+30.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+25.29%2023-09-11 → 2026-09-11$119.48 → $235.02 (+96.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+10.82%2021-09-10 → 2026-09-11$140.59 → $235.02 (+67.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+13.47%2016-09-09 → 2026-09-11$66.40 → $235.02 (+253.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 24.9×2016-09 17.312026-09 24.43+41.1% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 15.9×2016-09 9.462026-09 15.91+68.2% over the window
Fwd P/E: 19.5×
P/S (ttm)Market cap ÷ TTM revenue.: 2.2×2016-09 1.562026-09 2.24+43.5% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 3.5×2016-09 2.522026-09 3.45+37.2% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 19.2×2016-09 15.082026-09 19.23+27.5% over the window
EV/EBITDA (fy): 14.5×
EV/Sales (ttm): 2.8×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 5.20%2016-06 5.9%2026-06 5.7%-3.8% over the window
Dividend yield (fwd)Indicated forward annual dividend ÷ current price — the rate the company has announced, not what was actually paid over the past year.: 1.41%
Dividend/share (fwd): $3.32
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 110.4M ÷ 111.8M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 1.30%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (1.30%) + dividends paid over that year ($363M) ÷ market_cap_at(2025-06-30) ($20.1B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 3.10%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($552M) ÷ today's market cap ($25.9B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 2.13%2016-06 4.0%2026-06 2.3%-40.9% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $552M + TTM dividends $363M) ÷ today's market cap ($25.9B). Same caveat as the cash buyback yield.: 3.53%2016-06 5.8%2026-06 3.9%-33.5% over the window

Vs own 10Y history

P/E: 99th
P/OI: 99th
P/S: 99th
P/B: 99th
P/FCF: 91st

Bar = where today’s multiple sits in DGX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · windows as of 2026-09-11

+1.68%

-1.83%

-1.16%

+15.77%

YTD

+37.20%

+32.75%

+67.09%

Financial statements

Open full DGX financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	-8.44%	-0.65%
JNJ	Johnson & Johnson	+2.31%	-0.29%
ABBV	AbbVie Inc.	+3.36%	+0.83%
MRK	Merck & Co. Inc.	+8.28%	-0.54%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	-6.53%	-2.37%
TMO	Thermo Fisher Scientific Inc.	+1.13%	+1.10%
AMGN	Amgen Inc.	-8.80%	-1.34%
GILD	Gilead Sciences Inc.	+5.78%	-0.75%

Quest Diagnostics Incorporated (DGX) trades at $235.02 with a live price and an interactive chart covering 29+ years of daily price history, plus key valuation metrics. ChartRow also publishes DGX’s financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full DGX financial statements →

DGX — Quest Diagnostics Incorporated price, chart and key statistics